145 related articles for article (PubMed ID: 16856919)
1. Rapid infusion of rituximab with or without steroid-containing chemotherapy: 1-yr experience in a single institution.
Salar A; Casao D; Cervera M; Pedro C; Calafell M; Abella E; Alvarez-Larrán A; Besses C
Eur J Haematol; 2006 Oct; 77(4):338-40. PubMed ID: 16856919
[TBL] [Abstract][Full Text] [Related]
2. Rapid infusion rituximab changing practice for patient care.
Al Zahrani A; Ibrahim N; Al Eid A
J Oncol Pharm Pract; 2009 Sep; 15(3):183-6. PubMed ID: 19171551
[TBL] [Abstract][Full Text] [Related]
3. [Rituximab infusion-related toxicity in patients with chronic lymphocytic leukemia].
Šimkovič M; Vodárek P; Motyčková M; Žák P; Smolej L
Vnitr Lek; 2015; 61(7-8):626-32. PubMed ID: 26375688
[TBL] [Abstract][Full Text] [Related]
4. A phase I-II study to determine the maximum tolerated infusion rate of rituximab with special emphasis on monitoring the effect of rituximab on cardiac function.
Siano M; Lerch E; Negretti L; Zucca E; Rodriguez-Abreu D; Oberson M; Leoncini L; Mora O; Sessa C; Gallino A; Ghielmini M
Clin Cancer Res; 2008 Dec; 14(23):7935-9. PubMed ID: 19047125
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the safety and feasibility of rapid rituximab infusion.
Lang D; Prouse J; Barry F; Catherwood A; Chaplin K; Elliott L; Greco K; McGahey W; Nilsen J; Singhal N
Asia Pac J Clin Oncol; 2012 Mar; 8(1):71-5. PubMed ID: 22369446
[TBL] [Abstract][Full Text] [Related]
6. Rapid infusion of rituximab over 60 min.
Tuthill M; Crook T; Corbet T; King J; Webb A
Eur J Haematol; 2009 Apr; 82(4):322-5. PubMed ID: 19220420
[TBL] [Abstract][Full Text] [Related]
7. Use of a pharmacy protocol to convert standard rituximab infusions to rapid infusion shortens outpatient infusion clinic visits.
Swan JT; Zaghloul HA; Cox JE; Murillo JR
Pharmacotherapy; 2014 Jul; 34(7):686-94. PubMed ID: 24706572
[TBL] [Abstract][Full Text] [Related]
8. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance.
Byrd JC; Waselenko JK; Maneatis TJ; Murphy T; Ward FT; Monahan BP; Sipe MA; Donegan S; White CA
J Clin Oncol; 1999 Mar; 17(3):791-5. PubMed ID: 10071268
[TBL] [Abstract][Full Text] [Related]
9. [Rituximab and hematological malignancy].
Hatake K; Mishima Y; Terui Y
Nihon Rinsho; 2004 Jul; 62(7):1321-4. PubMed ID: 15283150
[TBL] [Abstract][Full Text] [Related]
10. A prospective study to evaluate the feasibility and economic benefits of rapid infusion rituximab at an Asian cancer center.
Chiang J; Chan A; Shih V; Hee SW; Tao M; Lim ST
Int J Hematol; 2010 Jun; 91(5):826-30. PubMed ID: 20461562
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan.
Tobinai K
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S90-6. PubMed ID: 12819934
[TBL] [Abstract][Full Text] [Related]
12. [Incidence of infusion reactions induced by cetuximab chemotherapy].
Maeda T; Tatematsu M; Muro K
Gan To Kagaku Ryoho; 2011 Jun; 38(6):963-6. PubMed ID: 21677487
[TBL] [Abstract][Full Text] [Related]
13. Prolonged remission in a patient with relapsed follicular lymphoma after a single course of rituximab.
Jensen M; Elter T; Engert A; Reiser M
Onkologie; 2006 Mar; 29(3):90-2. PubMed ID: 16514269
[TBL] [Abstract][Full Text] [Related]
14. Rituximab: a new monoclonal antibody therapy for non-Hodgkin's lymphoma.
Kosits C; Callaghan M
Oncol Nurs Forum; 2000; 27(1):51-9. PubMed ID: 10660923
[TBL] [Abstract][Full Text] [Related]
15. Tolerability and safety of rituximab (MabThera).
Kimby E
Cancer Treat Rev; 2005 Oct; 31(6):456-73. PubMed ID: 16054760
[TBL] [Abstract][Full Text] [Related]
16. Rapid rituximab infusion, local center experience.
Monem EA; Al-Bahrani B; Mehdi I; Nada A
Gulf J Oncolog; 2013 Jul; 1(14):52-6. PubMed ID: 23996867
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
18. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients.
Peñalver FJ; Jiménez-Yuste V; Almagro M; Alvarez-Larrán A; Rodríguez L; Casado M; Gallur L; Giraldo P; Hernández R; Menor D; Rodríguez MJ; Caballero D; González R; Mayans J; Millán I; Cabrera JR;
Ann Hematol; 2006 Jun; 85(6):400-6. PubMed ID: 16550390
[TBL] [Abstract][Full Text] [Related]
19. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
Gimsing P; Hansen M; Knudsen LM; Knoblauch P; Christensen IJ; Ooi CE; Buhl-Jensen P
Eur J Haematol; 2008 Sep; 81(3):170-6. PubMed ID: 18510700
[TBL] [Abstract][Full Text] [Related]
20. Acute coronary syndromes complicating the first infusion of rituximab.
Armitage JD; Montero C; Benner A; Armitage JO; Bociek G
Clin Lymphoma Myeloma; 2008 Aug; 8(4):253-5. PubMed ID: 18765315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
